A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity

Joan E. Smallshaw, Ellen S. Vitetta

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Ricin is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax) contains two mutations, rendering it non-toxic at high doses. Frozen or alum formulations of RiVax protected mice against ricin administered by injection, gavage or aerosol. Without alum, RiVax was safe and immunogenic in rabbits and human volunteers. For military use, the predominant target group, it would be optimal not to require a cold chain for transport and storage. We have now developed a lyophilized formulation and demonstrated stability and efficacy for at least 1 year stored refrigerated or at room temperature administered with or without alum.

Original languageEnglish (US)
Pages (from-to)2428-2435
Number of pages8
JournalVaccine
Volume28
Issue number12
DOIs
StatePublished - Mar 11 2010

Keywords

  • Lyophilization
  • Ricin
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity'. Together they form a unique fingerprint.

  • Cite this